Rheos Capital Works Inc. Invests $3.45 Million in Bruker Co. (NASDAQ:BRKR)

Rheos Capital Works Inc. bought a new stake in Bruker Co. (NASDAQ:BRKR) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the medical research company’s stock, valued at approximately $3,453,000.

A number of other institutional investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. lifted its position in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the period. Rise Advisors LLC acquired a new position in shares of Bruker in the first quarter valued at $27,000. Covestor Ltd lifted its position in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after purchasing an additional 210 shares during the period. UMB Bank n.a. boosted its stake in Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after buying an additional 354 shares in the last quarter. Finally, Gordian Capital Singapore Pte Ltd bought a new stake in Bruker in the 2nd quarter valued at $52,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group reduced their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Wells Fargo & Company initiated coverage on Bruker in a report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price objective on the stock. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup lowered their price target on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. Finally, Barclays started coverage on Bruker in a research note on Tuesday. They set an “overweight” rating and a $75.00 price objective for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.82.

Bruker Stock Down 2.9 %

Shares of NASDAQ BRKR opened at $61.27 on Thursday. Bruker Co. has a 12-month low of $53.79 and a 12-month high of $94.86. The firm’s 50-day simple moving average is $65.15 and its 200 day simple moving average is $69.44. The company has a market cap of $8.90 billion, a price-to-earnings ratio of 22.28, a price-to-earnings-growth ratio of 2.52 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. The firm had revenue of $800.70 million during the quarter, compared to analysts’ expectations of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. Bruker’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.50 EPS. On average, research analysts expect that Bruker Co. will post 2.61 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.33%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio is 7.27%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.